Why this article exists
Most of what is written about peptides on the public internet is not written by physicians. It is written by vendors, by influencers, and by people repeating what vendors and influencers have written. So when a peer-reviewed primer appears in a high-impact orthopedic journal — written by orthopedic and sports medicine physicians, for orthopedic and sports medicine physicians — it is worth pulling apart in public, paragraph by paragraph, and showing what the peer-reviewed authors actually say.
The 2026 American Journal of Sports Medicine primer — Mayfield, Bolia and colleagues, published by SAGE — does exactly the thing a primary-source review should do. It catalogs the named injectable peptides physicians keep being asked about, summarizes the mechanism, walks through what the human trial base actually contains, and is clear about the regulatory state. It does not promise anti-aging or "GH-level results." It also does not declare any of these molecules useless. It tries to live in the same gap a careful clinician has to live in.
Below is the read. For each peptide the journal covers, I have noted what the primer says, what the Limitless posture is, and whether the two agree.
BPC-157 — the most-claimed, least-trialed peptide on the list
The AJSM primer treats BPC-157 the way any honest review does. The preclinical literature is broad and unusually consistent — tendons, ligaments, gut lining, vascular endothelium, bone — and the proposed mechanism (modulation of growth-factor signaling, angiogenesis via VEGF/NO, FAK/paxillin in tendon fibroblasts) is mechanistically coherent across tissue types. The primer is also clear that the published human trial base in 2026 remains thin: a small number of published studies in inflammatory bowel disease and a cancelled Phase I program. There is no completed orthopedic RCT in humans. The peer-reviewed authors do not endorse routine clinical use on that basis.
This matches the standing Limitless posture exactly. BPC-157 sits in the recovery stack — combined with TB-500 — for tissue repair and slow recovery, prescribed inside an explicit disclosure to the patient that the human trial base is preclinical-heavy and that the FDA reclassification vote on July 23, 2026 is pending. The AJSM primer's caution is our caution. See the BPC-157 evidence brief for the same case in our own words.
TB-500 / Thymosin beta-4 — not interchangeable with BPC-157, even though they are stacked
The primer is careful to distinguish TB-500 (the synthetic fragment of thymosin beta-4 used in compounding) from the broader thymosin-beta-4 literature, including the prior clinical work in dermal wound healing and acute myocardial infarction. The mechanism is distinct from BPC-157 — actin sequestration, cell migration, anti-inflammatory signaling — which is precisely why a thoughtful recovery protocol stacks them rather than picking one. The journal flags the same regulatory state we do: TB-500 is on the July 23, 2026 PCAC docket, not currently on the 503A bulks list, and any compounded prescription requires a 503A pharmacy operating under that framework.
Limitless posture: stacked with BPC-157 in the recovery protocol. Same disclosure. Same regulatory pending status. The AJSM primer's framing is, again, the framing we already use.
CJC-1295 + ipamorelin — this is where the journal and the public internet diverge most sharply
The AJSM primer treats CJC-1295 + ipamorelin as a representative "GH secretagogue stack" — describes the mechanism (a GHRH analog and a ghrelin-receptor agonist working complementarily on the somatotroph), summarizes the biochemistry, and is candid about the relative scarcity of long-term efficacy and safety data in healthy adults. The journal does not pretend the stack is FDA-approved for any indication, and does not pretend the long-term hard-endpoint data exists.
Here is where the standing Limitless posture has, since 2026-05-13, diverged from a great deal of public peptide-clinic content. CJC-1295 is not on the current Limitless menu. The reason is regulatory, not clinical: multiple primary sources confirm that CJC-1295 is not currently legal for human compounding in 2026, is not on the July 23, 2026 PCAC docket, and would require a separate full rulemaking — typically more than a year after any future PCAC recommendation — before lawful human compounding could resume. The AJSM primer, written for an orthopedic audience, does not dwell on that point because it does not have to. We do, because we prescribe.
The GH-axis substitution is therefore intact and unchanged by this primer. Lead with tesamorelin, the only FDA-approved GHRH analog. Use sermorelin as an alternative where tesamorelin is not indicated or unavailable. Add ipamorelin only when the 503A partner pharmacy can dispense it under the current regulatory state. See the GH-axis evidence brief for the full case and the CJC-1295 status memo for the regulatory verification trail.
Tesamorelin — where the primer is at its strongest
The AJSM primer's tesamorelin section is the cleanest in the paper, because tesamorelin is the cleanest molecule in this class. The peer-reviewed authors note what we have already published at length on this site: tesamorelin is the only FDA-approved GHRH analog; it has a multi-trial Phase III dossier in HIV-associated visceral adiposity; the off-label hepatic-fat data is a randomized controlled signal on a hard endpoint with approximately one-third relative reduction in liver fat fraction; and the cognitive evidence (one RCT in mild cognitive impairment) is real but not load-bearing.
Limitless posture: tesamorelin is the GH-axis lead. The journal article does not change that — it reinforces it. See the GH-axis brief and the companion cognitive and metabolic evidence piece for our prescribing rules.
GHK-Cu — a Wave-2 PCAC peptide, watched but not on the menu
The primer includes GHK-Cu as an example of a small copper-binding peptide with intriguing dermal, hair, and wound-healing signals in the dermatologic and cosmeceutical literature. The injectable use case in orthopedic and regenerative settings is, at present, supported almost entirely by preclinical data and small open-label work. The peer-reviewed authors are explicit that GHK-Cu is not at the level of evidence required to recommend routine clinical injection for orthopedic indications.
This is consistent with the Limitless posture. GHK-Cu is on the menu of peptides we are watching as part of the Wave-2 PCAC docket — the early-2027 meeting we have written about in the post-PCAC peptide roadmap — and it is not currently on the prescribing menu. The journal's caution and our caution are the same.
The journal's framing, in one paragraph
Reading the AJSM primer end-to-end, the authors' overall framing is the same one this practice has settled into over the past year. The molecules are real. The mechanisms are mostly coherent. The marketing is wildly out ahead of the human trials. The regulatory state is in flux and matters enormously to what can actually be prescribed under U.S. compounding law. And the clinician's job is to live in that gap honestly — to acknowledge mechanism without overpromising, to acknowledge demand without selling the molecule, and to use the small subset that has the best risk/benefit ratio in patients who are clearly indicated for it.
The evidence, by molecule, as the primer reads it
| Peptide | What the AJSM primer says | Limitless posture |
|---|---|---|
| BPC-157 | Coherent preclinical mechanism across tendon/ligament/gut; human trial base thin; regulatory state pending. | On the recovery stack with TB-500. Explicit disclosure on the trial base. Pending PCAC vote 2026-07-23. |
| TB-500 | Distinct mechanism from BPC-157; broader thymosin-β4 prior work; same regulatory state. | Stacked with BPC-157 in the recovery protocol. Same posture. |
| CJC-1295 + ipamorelin | Representative GH-secretagogue stack; long-term human safety/efficacy data scarce. | CJC-1295 NOT on menu (regulatory, not clinical). Tesamorelin leads; ipamorelin conditional on 503A formulary. |
| Tesamorelin | FDA-approved GHRH analog; Phase III visceral-fat dossier; hepatic-fat RCT signal; cognitive signal real but small. | GH-axis lead. Posture unchanged by the primer; reinforced. |
| GHK-Cu | Dermal/hair/wound preclinical signal; not at orthopedic-injection evidence threshold. | Wave-2 PCAC watch only. Not on the prescribing menu. |
What this primer does and does not change
A peer-reviewed primer strengthens the conversation, not the prescription.
The AJSM primer is exactly the kind of public-facing peer-reviewed document that lets a physician have a more substantive conversation with a prospective patient about peptides. It is not a license to expand the prescribing menu. None of the molecules covered have a new indication, a new approval, or a new piece of hard-endpoint human trial data because of this paper — and the journal does not pretend otherwise.
The Limitless prescribing rules are unchanged. Lead with tesamorelin on the GH-axis. Stack BPC-157 + TB-500 for recovery with explicit disclosure. Add MOTS-c and NAD+ on the standing stack rules already documented in the MOTS-c brief and NAD+ evidence brief. Do not add CJC-1295 until the regulatory state actually permits it. Do not add GHK-Cu until the trial base earns it.
Foundations first, always. Peptides are layered on top of optimized sleep, training, nutrition, and any indicated hormone optimization — never instead of them.
What we tell every patient
- Peer-reviewed peptide reviews are now appearing in physician journals. That is good. It is also not the same thing as new RCT data, new FDA approvals, or new prescribing rules.
- The molecule you read about on a vendor site is rarely the same as the molecule a regulated 503A pharmacy can compound today. Always check the regulatory state.
- Limitless prescribes a deliberately narrow menu of peptides — the subset where the mechanism is coherent, the partner-pharmacy compounding is lawful, and the risk/benefit is defensible in writing to another physician.
- If a peptide is on a docket — like the July 23, 2026 PCAC vote on BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon and Semax — we will tell you what the docket is, what the possible outcomes are, and what it would change for your protocol.
- If a peptide is not on the menu and you ask why, you will get the answer in plain language. The honest version is on these pages.
What updates this article
This article will update when the July 23–24, 2026 PCAC vote is announced, when the early-2027 second PCAC meeting evaluates the Wave-2 peptides (GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF), and when any of the molecules in this primer accumulates the kind of human trial data that would actually move the prescribing posture. The standing posture in the box above governs every Limitless prescription as of 2026-05-26.